JP2009082136A5 - - Google Patents

Download PDF

Info

Publication number
JP2009082136A5
JP2009082136A5 JP2008297353A JP2008297353A JP2009082136A5 JP 2009082136 A5 JP2009082136 A5 JP 2009082136A5 JP 2008297353 A JP2008297353 A JP 2008297353A JP 2008297353 A JP2008297353 A JP 2008297353A JP 2009082136 A5 JP2009082136 A5 JP 2009082136A5
Authority
JP
Japan
Prior art keywords
cell
cells
seq
sequence
cell according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008297353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009082136A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009082136A publication Critical patent/JP2009082136A/ja
Publication of JP2009082136A5 publication Critical patent/JP2009082136A5/ja
Withdrawn legal-status Critical Current

Links

JP2008297353A 2001-07-05 2008-11-20 抗原性b型hivポリペプチドおよび/または抗原性c型hivポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 Withdrawn JP2009082136A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30319201P 2001-07-05 2001-07-05
US31686001P 2001-08-31 2001-08-31
US34972802P 2002-01-16 2002-01-16
US34987102P 2002-01-16 2002-01-16
US34979302P 2002-01-16 2002-01-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003510815A Division JP4302513B2 (ja) 2001-07-05 2002-07-05 抗原性b型hivポリペプチドおよび/または抗原性c型hivポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用

Publications (2)

Publication Number Publication Date
JP2009082136A JP2009082136A (ja) 2009-04-23
JP2009082136A5 true JP2009082136A5 (https=) 2009-10-08

Family

ID=27540889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003510815A Expired - Fee Related JP4302513B2 (ja) 2001-07-05 2002-07-05 抗原性b型hivポリペプチドおよび/または抗原性c型hivポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
JP2008297353A Withdrawn JP2009082136A (ja) 2001-07-05 2008-11-20 抗原性b型hivポリペプチドおよび/または抗原性c型hivポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003510815A Expired - Fee Related JP4302513B2 (ja) 2001-07-05 2002-07-05 抗原性b型hivポリペプチドおよび/または抗原性c型hivポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用

Country Status (6)

Country Link
US (1) US20030198621A1 (https=)
EP (3) EP2292772A1 (https=)
JP (2) JP4302513B2 (https=)
CA (1) CA2452119C (https=)
WO (1) WO2003004657A1 (https=)
ZA (1) ZA200400802B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CN1311871C (zh) 2000-03-02 2007-04-25 爱莫里大学 Dna表达载体及其应用方法
JP4554887B2 (ja) 2001-03-08 2010-09-29 アメリカ合衆国 改変HIVエンベロープ、gag、およびpol遺伝子を発現するMVA
EP2292772A1 (en) * 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
CN1606625A (zh) 2001-10-31 2005-04-13 南非医学研究会 Hiv-1亚型分离株调节/附加基因及其修饰物和衍生物
JP2006502228A (ja) * 2002-10-07 2006-01-19 カイロン コーポレイション Hivワクチン処方物
US20060205070A1 (en) * 2004-01-13 2006-09-14 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services HIV TEV compositions and methods of use
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
GB0802224D0 (en) * 2008-02-06 2008-03-12 Inst Superiore Di Sanito Process for the production of vaccine components
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
JP2016535989A (ja) 2013-11-01 2016-11-24 ファイザー・インク 前立腺関連抗原を発現させるためのベクター
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
PT3390430T (pt) 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Hivワクチン製剤
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
JP2021532742A (ja) * 2018-07-26 2021-12-02 ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. Nefを含むt細胞及びその生成方法
WO2025007009A2 (en) * 2023-06-30 2025-01-02 The Trustees Of The University Of Pennsylvania Mrna-encoded tat with attenuated cytotoxicity for hiv and siv latency reversal

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1984A (en) 1841-02-18 Machinery for trimming straw braid
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5843638A (en) * 1983-12-05 1998-12-01 Institut Pasteur And Centre National De La Recherche Scientifique Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1).
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0165942A1 (en) 1983-12-23 1986-01-02 Monash University PRODUCTION OF HUMAN INTERFERON-$g(a)
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US6001977A (en) * 1984-08-22 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US5032510A (en) * 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4879227A (en) 1986-05-06 1989-11-07 Genetics Institute, Inc. Production of a recombinant human colony stimulating factor
US5034511A (en) * 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
US5135855A (en) 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
US5637677A (en) * 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US5879907A (en) * 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
WO1989009271A1 (en) 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
EP0434713B1 (en) 1988-09-13 1994-10-12 Chiron Corporation Hiv-1 envelope muteins lacking hypervariable domains
WO1990006370A1 (en) 1988-12-01 1990-06-14 The Trustees Of The University Of North Carolina Synthetic interleukin-6
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ(ユーケー)リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
ES2072346T3 (es) * 1989-10-23 1995-07-16 Hoffmann La Roche Peptidos sinteticos de la cubierta del htlv-i.
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
EP0449116B2 (en) 1990-03-21 2004-08-25 Geneart GmbH DNA sequences encoding modified retroviral gag polypeptides and vaccines containing them or aggregates thereof
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2405246A1 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
IE920366A1 (en) * 1991-02-04 1992-08-12 Univ Saskatchewan Vp6 encapsulated drug delivery
JPH06508821A (ja) * 1991-03-07 1994-10-06 セラジュン インク ウイルス病治療のための細胞表面受容体を標的とする分子の使用
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5558865A (en) * 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
CA2084386C (en) * 1992-06-04 2001-02-20 Atsushi Saito Hiv antigen
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
CA2141188A1 (en) 1992-07-27 1994-02-03 New York University High field magnets for medical applications
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5686078A (en) * 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5304472A (en) * 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DK0679187T4 (da) * 1993-01-16 2001-09-17 Manfred Schawaller Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
US5419900A (en) * 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
EP0708659A4 (en) * 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDES
CA2164818C (en) 1993-06-09 2003-09-23 Charles D.Y. Sia Tandem synthetic hiv-1 peptides
US5614413A (en) * 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6291157B1 (en) * 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5550280A (en) * 1994-11-30 1996-08-27 Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee Hindered aromatic ester compounds useful as anti-viral agents
DK0800579T3 (da) 1994-12-30 2002-09-09 Chiron Corp Kombinations-gen-leveringsvehikler
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6087486A (en) * 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
US6060587A (en) * 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
DE69738521T2 (de) 1996-04-05 2009-05-07 Novartis Vaccines and Diagnostics, Inc., Emeryville Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
ATE229073T1 (de) * 1996-09-06 2002-12-15 Univ California Protein e25a, methoden zu dessen herstellung und anwendung
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
DK0969862T3 (da) 1997-02-07 2007-02-12 Merck & Co Inc Syntetisk HIV gag-gener
US5858675A (en) * 1997-05-13 1999-01-12 Incyte Pharmaceuticals, Inc. Double-stranded RNA-binding protein
US6099847A (en) * 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
US6846905B2 (en) * 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5932445A (en) * 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
AU3745599A (en) * 1998-04-14 1999-11-01 Chiron Corporation Noncloning technique for expressing a gene of interest
AU5677399A (en) * 1998-08-20 2000-03-14 Wistar Institute Of Anatomy And Biology, The Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
ES2299276T3 (es) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP2003513635A (ja) * 1999-11-01 2003-04-15 カイロン コーポレイション 発現ベクター、トランスフェクション系、およびそれらの使用方法
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
EP2292772A1 (en) * 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
WO2008086329A2 (en) 2007-01-08 2008-07-17 Continental Automotive Systems Us, Inc. Dc/dc converter
US8974986B2 (en) 2007-07-06 2015-03-10 M. Technique Co., Ltd. Method for producing metal-supported carbon, method for producing crystals consisting of fullerene molecules and fullerene nanowhisker/nanofiber nanotubes, and apparatus for producing the same
EP2510962A1 (en) 2011-04-12 2012-10-17 F. Hoffmann-La Roche AG Infusion pump device with re-filling scheme for cylinder-piston dosing unit

Similar Documents

Publication Publication Date Title
JP2009082136A5 (https=)
US20220331399A1 (en) Methods of using zscan4 for rejuvenating human cells
JP2004502445A5 (https=)
IL299249B1 (en) Genetically modified immune cells that include adapted shrna-microRNA (shrnamir)
JP2012509678A5 (https=)
DE502007006746D1 (de) Rsv f-protein und seine verwendung
JP2004267216A5 (https=)
JP2002539793A5 (https=)
EP3792348A3 (en) Mutated rep encoding sequences for use in aav production
FI3889173T3 (fi) Optimoitu tekijä viii:n geeni
JP2006502748A5 (https=)
JP2005058227A5 (https=)
JP2006149395A5 (https=)
JP2013507935A5 (https=)
JP2009511014A5 (https=)
JP2005521380A5 (https=)
Ahola et al. Organization and expression of the transforming region from the European elk papillomavirus (EEPV)
MY159849A (en) Mammalian expression vector
JP2021529519A5 (https=)
JP2003334088A5 (https=)
Cheung et al. Bacterial delivery of large intact genomic-DNA-containing BACs into mammalian cells
RU2009134183A (ru) Днк-вакцины на основе полноразмерного м-сегмента вируса пуумала
JP2009232836A5 (https=)
JPH11178A5 (https=)
JP2007513601A5 (https=)